Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.

449.74 10.07 −2.19%
Market cap
$10.6B
P/E
0.0×
Fwd P/E
−71.3×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(53.31%) (49.35%) (42.49%) (41.22%)

+8 more TTM periods

ROA
(28.77%) (27.83%) (25.05%) (23.74%)
ROIC
(787.33%) (297.52%) 0.00% 0.00%
Return on Tangible Assets
(38.86%) (36.32%) (30.77%) (30.17%)
Average Days of Receivables
54.67 60.38 51.21 55.83
Free Cash Flow per Share
(7.08) (9.39) (8.65) (7.36)
Free Cash Flow
(206.28) (272.61) (193.99) (165.54)
Other line items

Show all line items

Columns are period end dates